Dr. Cytryn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 53rd St
New York, NY 10022Phone+1 212-639-2000
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2017 - 2020
Icahn School of Medicine at Mount SinaiClass of 2017
Certifications & Licensure
NY State Medical License 2019 - 2026
NJ State Medical License 2024 - 2025
CT State Medical License 2024 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Start of enrollment: 2024 Feb 01
Roles: Contact
Publications & Presentations
PubMed
- 4 citationsFirst-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre,...Samuel L Cytryn, Ryan H Moy, Darren Cowzer, Ronak H Shah, Joanne F Chou
The Lancet. Oncology. 2023-10-01 - 2 citationsHER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.Samuel L Cytryn, Yelena Y Janjigian
Journal of the National Comprehensive Cancer Network. 2023-04-01 - 21 citationsHaploidentical Hematopoietic Stem Cell Transplantation Followed by 'Post-Cyclophosphamide': The Future of Allogeneic Stem Cell Transplant.Samuel Cytryn, Maher Abdul-Hay
Clinical Hematology International. 2020-04-19
Press Mentions
Bispecific Antibodies in Gastric Cancer: Big Questions but Bigger Potential?August 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
